Principles and Practice of Pharmaceutical Medicine

Andrew J Fletcher
Temple University, Pennsylvania, USA

Lionel D Edwards
Novartis and Pharma Pro Plus Inc, New Jersey, USA

Anthony W Fox
EBD Group Inc, Carlsbad, California, USA

Peter Stonier
Consultant in Pharmaceutical Medicine, Surrey, UK
Contents

About the Editors ........................................ ix
List of Contributors ..................................... xi
Preface .................................................. xiii

Section I: Overview of Pharmaceutical Medicine

1 Pharmaceutical Medicine as a Medical Speciality ......................... 3
   Michael D. Young

2 What Pharmaceutical Medicine Is and Who Does It ....................... 13
   W. Wardell and Susan Toland
   and Anthony W. Fox

3 Competency-based Training System for Clinical Research Staff ........ 17
   Jay D. Miller

Section II: Drug Discovery and Development

Introduction ............................................... 30
   Lionel D. Edwards and
   Anthony W. Fox

4 Drug Discovery: Design and Serendipity .................................. 31
   Leslie J. Molony

5 Pharmaceutics ........................................... 45
   Anthony W. Fox

6 Non-clinical Toxicology ........................................ 55
   Frederick Reno

7 Informed Consent ......................................... 65
   Anthony W. Fox

8 Good Clinical Practices ....................................... 69
   Wendy Bohaychuk and Graham Ball

9 Quality Assurance, Quality Control and Audit ............................ 85
   Donna Cullen

10 Phase I: The First Opportunity for Extrapolation from Animal Data
to Human Experience ....................................... 95
   Stephen Curry, Dennis McCarthy,
   Heleen H. DeCory Matthew Marler
   and Johan Gabrielsson

11 Phase II and Phase III Clinical Studies ................................. 117
   Anthony W. Fox

12 Phase IV Drug Development: Post-marketing Studies ................. 133
   Lisa R. Johnson-Pratt

13 Over-the-counter Medicines ........................................ 141
   Paul Starkey

Section III: Special Populations

Introduction ............................................... 154
   Lionel D. Edwards

14 Drug Research in Older Patients .................................. 157
   Lionel D. Edwards

15 Drug Development Research in Women ............................... 165
   Lionel D. Edwards

16 Clinical Research in Children .................................... 183
   Lionel D. Edwards
Section IV:  Applied Aspects of Drug Development

Introduction .................................................. 190  
  Anthony W. Fox

17 Biotechnology Products and Their Development ................. 191  
  David Shapiro and Anthony W. Fox

18 Orphan Drugs ............................................ 203  
  Bert Spilker

19 Pharmacoeconomics: Economic and Humanistic Outcomes ........ 211  
  Raymond J. Townsend, Jane T. Osterhaus and J. Gregory Boyer

20 Pharmacoepidemiology and the Pharmaceutical Physician ....... 223  
  Hugh Tilson

21 Statistical Principles and Their Application in Biopharmaceutical Research ............................................. 231  
  Dan Anbar

22 Data Management ......................................... 259  
  T.Y. Lee and Michael Minor

23 Patient Compliance ....................................... 269  
  Jean-Michel Métroy

24 Complementary Medicines .................................. 281  
  Anthony W. Fox

Section V:  Drug Registration

Introduction .................................................. 288  
  Anthony W. Fox

25 United States Regulations .................................. 289  
  William Kennedy

26 Emergency and Compassionate-use INDs and Accelerated NDA or ANDA Approvals—Procedures, Benefits and Pitfalls .............. 299  
  Anthony W. Fox

27 Japanese Regulations ...................................... 307  
  Etienne Labbé

28 The Development of Human Medicines Control in Europe from Classical Times to the Year 2000 ........................................ 325  
  John Griffin

29 Ethnic Issues in Drug Registration .......................... 347  

Section VI:  Medical Services

Introduction .................................................. 364  
  Anthony W. Fox

30 An Introduction to Medical Affairs .................................. 365  
  Gill Price

31 Drug Labeling ............................................ 371  
  Anthony W. Fox

32 Organizing and Planning Local, Regional, National and International Meetings and Conferences .............................. 375  
  Zofia E. Dziewanowska, Linda Packard and Lionel D. Edwards

33 Drug Surveillance .......................................... 379  
  Howard J. Dreskin and Win M. Castle

34 Disease Management—What Does It Mean? ...................... 389  
  Roy Lilley
Section VII: Legal and Ethical Aspects

Introduction ........................................ 414
Sara Croft and Tim Pratt

36 Pharmaceutical Product Liability ...... 421
Han W. Choi and Howard B. Yeon

37 Patents .............................................. 431
Gabriel Lopez

38 Fraud and Misconduct in Clinical Research ........ 441
Frank Wells

Section VIII: Business Aspects

39 The Multinational Corporations: Cultural Challenges, the Legal/Regulatory Framework and the Medico-commercial Environment ........ 453
R. Drucker and R. Graham Hughes

40 Outsourcing Clinical Drug Development Activities to Contract Research Organizations (CROs): Critical Success Factors ........ 461
John R. Vogel

41 The Third World ............................... 483
Gamal Hammad

42 Financial Aspects of Clinical Trials .... 501
R. Graham Hughes and N. Turner

43 The Impact of Managed Care on the US Pharmaceutical Industry .... 513
Robert Chaponis, Christine Hanson-Divers and Marilyn J. Wells

Appendix—Useful Internet Links ............ 529
Index ................................................. 531